U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H36O5
Molecular Weight 404.5406
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LOVASTATIN

SMILES

CC[C@]([H])(C)C(=O)O[C@@]1([H])C[C@@]([H])(C)C=C2C=C[C@]([H])(C)[C@]([H])(CC[C@]3([H])C[C@]([H])(CC(=O)O3)O)[C@]21[H]

InChI

InChIKey=PCZOHLXUXFIOCF-BXMDZJJMSA-N
InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1

HIDE SMILES / InChI

Molecular Formula C24H36O5
Molecular Weight 404.5406
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including https://clinicaltrials.gov/show/NCT00580970 | http://medical-dictionary.thefreedictionary.com/lovastatin

Lovastatin acid is an active metabolite of hypolipidemic drug Lovastatin. Lovastatin acid inhibits HMG-CoA reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate limiting step in the biosynthesis of cholesterol. Lovastatin has been shown to reduce both normal and elevated low-density lipoprotein cholesterol (LDL-C). Lovastatin in approved for prevention of cardiovascular events and hypercholesterolemia. Off-label use of lovastatin includes treatmetn of diabetic dyslipidemia, familial dysbetalipoproteinemia, familial combined hyperlipidemia, or nephrotic hyperlipidemia. Lovastatin was tested in clinical trials agains radioation injury during therapy of prostate cancer.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.64 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
ALTOPREV

Approved Use

1.1 Prevention of Coronary Heart Disease In patients without symptomatic coronary heart disease (CHD), but at high risk, Altoprev® is indicated to reduce the risk of: Myocardial infarction; Unstable angina; Coronary revascularization procedures; Coronary Heart Disease. Altoprev is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower Total-C and LDL-C to target levels. Hyperlipidemia Altoprev is indicated as an adjunct to diet for the reduction of elevated Total-C, LDL-C, Apo B, and TG, and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson types IIa and IIb).

Launch Date

1.01200318E12
Palliative
ALTOPREV

Approved Use

1.1 Prevention of Coronary Heart Disease In patients without symptomatic coronary heart disease (CHD), but at high risk, Altoprev® is indicated to reduce the risk of: Myocardial infarction; Unstable angina; Coronary revascularization procedures; Coronary Heart Disease. Altoprev is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower Total-C and LDL-C to target levels. Hyperlipidemia Altoprev is indicated as an adjunct to diet for the reduction of elevated Total-C, LDL-C, Apo B, and TG, and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson types IIa and IIb).

Launch Date

1.01200318E12
Preventing
MEVACOR

Approved Use

After oral ingestion, lovastatin, which is an inactive lactone, is hydrolyzed to the lovastatin acid. This is a principal metabolite and an inhibitor of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate limiting step in the biosynthesis of cholesterol. Lovastatin has been shown to reduce both normal and elevated low-density lipoprotein cholesterol (LDL-C).

Launch Date

5.5728E11
Primary
MEVACOR

Approved Use

Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. MEVACOR is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate.

Launch Date

5.5728E11
Secondary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
17.6 ng/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
11.9 ng/mL
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
76.9 ng × h/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
83 ng × h/mL
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.5 h
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Disc. AE: Aspartate aminotransferase increased, Alanine aminotransferase increased...
AEs leading to
discontinuation/dose reduction:
Aspartate aminotransferase increased (grade 2-4, 1.3%)
Alanine aminotransferase increased (grade 2-4, 1.3%)
Gastrointestinal disturbance (0.4%)
Rash (0.27%)
Myalgia (0.13%)
Myopathy (0.27%)
Arthralgia (0.13%)
Insomnia (0.13%)
Weight gain (0.13%)
Sources: Page: p.1082, 1083
10 mg/kg 4 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 6
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 6
Sources: Page: p.527
DLT: Creatine phosphokinase increased, Aspartate aminotransferase increased...
Dose limiting toxicities:
Creatine phosphokinase increased (grade 4, 33.3%)
Aspartate aminotransferase increased (grade 2-3, 33.3%)
Alanine aminotransferase increased (grade 2-3, 33.3%)
Sources: Page: p.527
7.5 mg/kg 4 times / day multiple, oral (total daily dose)
MTD
Dose: 7.5 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 7.5 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 7
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 7
Sources: Page: p.527
DLT: Creatine phosphokinase increased, Aspartate aminotransferase increased...
Dose limiting toxicities:
Creatine phosphokinase increased (grade 4, 28.6%)
Aspartate aminotransferase increased (grade 3, 14.3%)
Alanine aminotransferase increased (grade 3, 14.3%)
Sources: Page: p.527
AEs

AEs

AESignificanceDosePopulation
Arthralgia 0.13%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Insomnia 0.13%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Myalgia 0.13%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Weight gain 0.13%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Myopathy 0.27%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Rash 0.27%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Gastrointestinal disturbance 0.4%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Alanine aminotransferase increased grade 2-4, 1.3%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Aspartate aminotransferase increased grade 2-4, 1.3%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Alanine aminotransferase increased grade 2-3, 33.3%
DLT
10 mg/kg 4 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 6
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 6
Sources: Page: p.527
Aspartate aminotransferase increased grade 2-3, 33.3%
DLT
10 mg/kg 4 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 6
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 6
Sources: Page: p.527
Creatine phosphokinase increased grade 4, 33.3%
DLT
10 mg/kg 4 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 6
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 6
Sources: Page: p.527
Alanine aminotransferase increased grade 3, 14.3%
DLT
7.5 mg/kg 4 times / day multiple, oral (total daily dose)
MTD
Dose: 7.5 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 7.5 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 7
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 7
Sources: Page: p.527
Aspartate aminotransferase increased grade 3, 14.3%
DLT
7.5 mg/kg 4 times / day multiple, oral (total daily dose)
MTD
Dose: 7.5 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 7.5 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 7
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 7
Sources: Page: p.527
Creatine phosphokinase increased grade 4, 28.6%
DLT
7.5 mg/kg 4 times / day multiple, oral (total daily dose)
MTD
Dose: 7.5 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 7.5 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 7
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 7
Sources: Page: p.527
PubMed

PubMed

TitleDatePubMed
Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment.
1999 Apr
Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells.
1999 Aug
Effect of lipid-lowering strategies on tubular cell biology.
1999 Jul
Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases.
1999 Mar
Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac.
1999 Oct
Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture.
2000 Jun
Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice.
2000 May
The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer.
2001
The effects of the statins lovastatin and cerivastatin on signalling by the prostanoid IP-receptor.
2001 Apr
A new simvastatin (mevinolin)-resistance marker from Haloarcula hispanica and a new Haloferax volcanii strain cured of plasmid pHV2.
2001 Apr
Comparative study of HMG-CoA reductase inhibitors on fibrinogen.
2001 Apr
Rho GTPases are involved in the regulation of NF-kappaB by genotoxic stress.
2001 Apr 1
Statins are magic when you gotta have heart.
2001 Apr 16
[Statins and diabetic hyperlipidemia].
2001 Feb
[Kidney and statins].
2001 Feb
Cholesterol biosynthesis from lanosterol: molecular cloning, chromosomal localization, functional expression and liver-specific gene regulation of rat sterol delta8-isomerase, a cholesterogenic enzyme with multiple functions.
2001 Feb 1
Cholesterol-dependent modulation of tau phosphorylation in cultured neurons.
2001 Jan
Fragmentation study of simvastatin and lovastatin using electrospray ionization tandem mass spectrometry.
2001 Jan
New statins and new doses of older statins.
2001 Jan
Heart disease. Rethinking treatments for the heart.
2001 Jan 15
[The role of HDL in the prevention of cardiovascular events].
2001 Jan 21
Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia.
2001 Jun
Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection.
2001 Jun
Recent advances in the biosynthetic studies of lovastatin.
2001 Mar
[AFCAPS/TexCAPS [The Air Force/Texas Coronary Atherosclerosis Prevention Study]].
2001 Mar
HMG-CoA reductase inhibitors and P-glycoprotein modulation.
2001 Mar
High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol.
2001 Mar 15
3-Hydroxy-3-methylglutaryl coenzyme A synthase-1 of Blattella germanica has structural and functional features of an active retrogene.
2001 Mar 15
Revised indications for statin therapies.
2001 May
What do the statin trials tell us?
2001 May
Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease.
2001 May
Can modulation of endothelial nitric oxide synthase explain the vasculoprotective actions of statins?
2001 May
Cholesterol ester accumulation: an immediate consequence of acute in vivo ischemic renal injury.
2001 May
Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin.
2001 May 1
Lovastatin controls signal transduction in vascular smooth muscle cells by modulating phosphorylation levels of mevalonate-independent pathways.
2001 May-Jun
Cost effectiveness of HMG-CoA reductase inhibition in Canada.
2001 Spring
Patents

Sample Use Guides

Hyperlipidemia and Mixed Dyslipidemia: (Fredrickson Types IIa and IIb). The recommended dosing range is 20-60 mg/day, in single doses taken in the evening at bedtime.
Route of Administration: Oral
Flow cytometry revealed significant increases in three of four lung cancer cell lines in apoptosis and necrosis after lovastatin treatment at 10 uM for 72 h. Lovastatin adversely affected lung cancer cell survival with increases in cell-cycle check-point inhibitors p21WAF and/or p27KIP and a decrease in cyclin D1. All four lung cancer cell lines had a decrease in glutathione after lovastatin treatment consistent with reduced protection against reactive oxidant species. Three of four lung cancer cell lines had increased cytochrome c release with reduced pro-caspase-3 and increases in activated caspase-3. Lovastatin induces apoptosis and necrosis in lung cancer cell lines by causing alterations in the cell cycle, reducing glutathione, and activating p53, Bax protein, and caspases while increasing cytochrome c in apoptosis pathways.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:03:59 UTC 2021
Edited
by admin
on Fri Jun 25 21:03:59 UTC 2021
Record UNII
9LHU78OQFD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LOVASTATIN
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
(S)-2-METHYLBUTYRIC ACID, 8-ESTER WITH (4R,6R)-6-(2-((1S,2S,6R,8S,8AR)-1,2,6,7,8,8A-HEXAHYDRO-8-HYDROXY-2,6-DIMETHYL-1-NAPHTHYL)ETHYL)TETRAHYDRO-4-HYDROXY-2H-PYRAN-2-ONE
Common Name English
SIMVASTATIN IMPURITY, LOVASTATIN- [USP]
Common Name English
LOVASTATIN [USP-RS]
Common Name English
LOVASTATIN [WHO-DD]
Common Name English
MEVLOR
Brand Name English
LOVASTATIN COMPONENT OF ADVICOR
Common Name English
SIVLOR
Brand Name English
LOVASTATIN [EP MONOGRAPH]
Common Name English
SIMVASTATIN SPECIFIED IMPURITY E [EP]
Common Name English
LOVASTATIN [INN]
Common Name English
ALTOPREV
Brand Name English
LOVASTATIN [USP MONOGRAPH]
Common Name English
MEVINOLIN
Common Name English
L-154803
Code English
LOVASTATIN [ORANGE BOOK]
Common Name English
MONACOLIN K
Common Name English
MK-803
Code English
LOVASTATIN [HSDB]
Common Name English
LOVASTATIN [MI]
Common Name English
LOVASTATIN [MART.]
Common Name English
C10AA02
Code English
LOVASTATIN [USAN]
Common Name English
BUTANOIC ACID, 2-METHYL-, 1,2,3,7,8,8A-HEXAHYDRO-3,7-DIMETHYL-8-(2-(TETRAHYDRO-4-HYDROXY-6-OXO-2H-PYRAN-2-YL)ETHYL)-1-NAPHTHALENYL ESTER, (1S-(1.ALPHA.(R*),3.ALPHA.,7.BETA.,8.BETA.(2S*,4S*),8.ALPHA..BETA.))-
Common Name English
ADVICOR COMPONENT LOVASTATIN
Common Name English
(2S)-2-METHYLBUTANOIC ACID (1S,3R,7S,8S,8AR)-1,2,3,7,8,8A-HEXAHYDRO-3,7-DIMETHYL-8-(2-((2R,4R)-TETRAHYDRO-4-HYDROXY-6-OXO-2H-PYRAN-2-YL)ETHYL)-1-NAPHTHALENYL ESTER
Common Name English
MEVINACOR
Brand Name English
LOVASTATIN [VANDF]
Common Name English
NSC-758662
Code English
MEVACOR
Brand Name English
6.ALPHA.-METHYLCOMPACTIN
Common Name English
Classification Tree Code System Code
WHO-ATC C10AA02
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
LIVERTOX 574
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
WHO-ATC C10BA01
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
NCI_THESAURUS C54679
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
WHO-VATC QC10BA01
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
WHO-VATC QC10AA02
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
NDF-RT N0000000121
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
NCI_THESAURUS C1655
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
NDF-RT N0000175589
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
Code System Code Type Description
HSDB
6534
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
PRIMARY
FDA UNII
9LHU78OQFD
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
PRIMARY
INN
6074
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
PRIMARY
MERCK INDEX
M6914
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL503
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
PRIMARY
EPA CompTox
75330-75-5
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
PRIMARY
USP_CATALOG
1370600
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
PRIMARY USP-RS
LACTMED
Lovastatin
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
PRIMARY
MESH
D008148
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
PRIMARY
DRUG BANK
DB00227
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
PRIMARY
RXCUI
6472
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C620
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
PRIMARY
PUBCHEM
53232
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
PRIMARY
EVMPD
SUB08604MIG
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
PRIMARY
DRUG CENTRAL
1612
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
PRIMARY
CAS
75330-75-5
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
PRIMARY
IUPHAR
2739
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
PRIMARY
WIKIPEDIA
LOVASTATIN
Created by admin on Fri Jun 25 21:03:59 UTC 2021 , Edited by admin on Fri Jun 25 21:03:59 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
TRANSPORTER -> INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
CYP3A
PLASMA
METABOLITE ACTIVE -> PRODRUG
METABOLITE -> PARENT
In Vitro metabolite; CYP3A
IN-VITRO
Related Record Type Details
IMPURITY -> PARENT
correction factor: for the calculation of content, multiply the peak area of impurity E by 1.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
sum of impurities E and F: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
MAXIMUM TOLERATED DOSE TOXICITY
ORAL BIOAVAILABILITY PHARMACOKINETIC